Email Alert RSS
Volume 14 Issue 3
May  2023
Turn off MathJax
Article Contents
Abstract
References
Related Articles
LI Tao, ZHANG Kan, YANG Wenyu, LIU Lu, ZHENG Xuan, ZHANG Fan, HU Yi. Clinical Application of Immune Checkpoint Inhibitors CTLA-4 in Solid Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(3): 652-659. DOI: 10.12290/xhyxzz.2022-0617
Citation: LI Tao, ZHANG Kan, YANG Wenyu, LIU Lu, ZHENG Xuan, ZHANG Fan, HU Yi. Clinical Application of Immune Checkpoint Inhibitors CTLA-4 in Solid Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(3): 652-659. DOI: 10.12290/xhyxzz.2022-0617
shu

Clinical Application of Immune Checkpoint Inhibitors CTLA-4 in Solid Tumors

  • 1.

    Department of Oncology, Chinese PLA Key Laboratory of Oncology, Ministry of Education Key Laboratory for Tumor Targeting Therapy and Antibody Drugs, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China

  • 2.

    Graduate School, Chinese PLA General Hospital(Chinese PLA Medical School), Beijing 100853, China

  • 3.

    Department of Respiratory, the Eighth Medical Center of Chinese PLA General Hospital, Beijing 100853, China

  • 4.

    School of Medicine, Nankai University, Tianjin 300000, China

  • 5.

    Department of Nutrition, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China

Funds: 

Special Key Project of National Health Commission of China GWJJ2021100304

More Information
  • Corresponding author:

    HU Yi, E-mail: huyi301zlxb@sina.com

  • Received Date: October 23, 2022
  • Accepted Date: December 11, 2022
  • Issue Publish Date: May 29, 2023
    Graphical Abstract
    • Abstract
  • In recent years, immunotherapy has become a new method for solid tumor treatment, and a large number of immune preparations have been developed and applied in clinical practice. Among them, immune checkpoint inhibitors (ICIs) are widely used, ushering in a new era for tumor treatment. In particular, cytotoxic T-lymphocyte-associated protein 4(CTLA-4), as a representative drug, enriches tumor immunotherapy methods and opens up a new treatment mode of dual immunotherapy. This article reviews the clinical application progress of CTLA-4 in the treatment of advanced solid tumors, with the hope of providing reference for immunotherapy of tumors.
    • FullText(HTML)
    • References (51)
  • [1]
    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144: 646-674. DOI: 10.1016/j.cell.2011.02.013
    [2]
    Hanahan D. Hallmarks of Cancer: New Dimensions[J]. Cancer Discov, 2022, 12: 31-46. DOI: 10.1158/2159-8290.CD-21-1059
    [3]
    Ephraim R, Fraser S, Nurgali K, et al. Checkpoint Markers and Tumor Microenvironment: What Do We Know?[J]. Cancers (Basel), 2022, 14: 3788. DOI: 10.3390/cancers14153788
    [4]
    Maruhashi T, Sugiura D, Okazaki IM, et al. LAG-3: from molecular functions to clinical applications[J]. J Immunother Cancer, 2020, 8: e001014. DOI: 10.1136/jitc-2020-001014
    [5]
    Freed-Pastor WA, Lambert LJ, Ely ZA, et al. The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer[J]. Cancer Cell, 2021, 39: 1342-1360. DOI: 10.1016/j.ccell.2021.07.007
    [6]
    Azuma M, Ito D, Yagita H, et al. B70 antigen is a second ligand for CTLA-4 and CD28[J]. Nature, 1993, 366: 76-79. DOI: 10.1038/366076a0
    [7]
    Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells[J]. J Exp Med, 1996, 183: 2533-2540. DOI: 10.1084/jem.183.6.2533
    [8]
    Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms[J]. Mol Cell Biol, 2005, 25: 9543-9553. DOI: 10.1128/MCB.25.21.9543-9553.2005
    [9]
    Ribas A. Releasing the Brakes on Cancer Immunotherapy[J]. N Engl J Med, 2015, 373: 1490-1492. DOI: 10.1056/NEJMp1510079
    [10]
    Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4[J]. J Exp Med, 2000, 192: 303-310. DOI: 10.1084/jem.192.2.303
    [11]
    Qureshi OS, Zheng Y, Nakamura K, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4[J]. Science, 2011, 332: 600-603. DOI: 10.1126/science.1202947
    [12]
    Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy[J]. Cancer Discov, 2018, 8: 1069-1086. DOI: 10.1158/2159-8290.CD-18-0367
    [13]
    Hou TZ, Qureshi OS, Wang CJ, et al. A transendocytosis model of CTLA-4 function predicts its suppressive behavior on regulatory T cells[J]. J Immunol, 2015, 194: 2148-2159. http://pubmed.ncbi.nlm.nih.gov/25632005/
    [14]
    Pedicord VA, Montalvo W, Leiner IM, et al. Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance[J]. Proc Natl Acad Sci USA, 2011, 108: 266-271. DOI: 10.1073/pnas.1016791108
    [15]
    Weber JS, Hamid O, Chasalow SD, et al. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma[J]. J Immunother, 2012, 35: 89-97. DOI: 10.1097/CJI.0b013e31823aa41c
    [16]
    Selby MJ, Engelhardt JJ, Quigley M, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells[J]. Cancer Immunol Res, 2013, 1: 32-42. DOI: 10.1158/2326-6066.CIR-13-0013
    [17]
    Sharma A, Subudhi SK, Blando J, et al. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3(+) Regulatory T Cells (Tregs) in Human Cancers[J]. Clin Cancer Res, 2019, 25: 1233-1238. DOI: 10.1158/1078-0432.CCR-18-0762
    [18]
    Felix J, Lambert J, Roelens M, et al. Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response[J]. Oncoimmunology, 2016, 5: 1136045. DOI: 10.1080/2162402X.2015.1136045
    [19]
    Gubin MM, Esaulova E, Ward JP, et al. High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy[J]. Cell, 2018, 175: 1014-1030. DOI: 10.1016/j.cell.2018.09.030
    [20]
    Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer[J]. J Exp Clin Cancer Res, 2019, 38: 255. DOI: 10.1186/s13046-019-1259-z
    [21]
    Willsmore ZN, Coumbe B, Crescioli S, et al. Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action[J]. Eur J Immunol, 2021, 51: 544-556. DOI: 10.1002/eji.202048747
    [22]
    McDermott D, Haanen J, Chen TT, et al. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase Ⅲ trial (MDX010-20)[J]. Ann Oncol, 2013, 24: 2694-2698. DOI: 10.1093/annonc/mdt291
    [23]
    Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage Ⅲ melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2015, 16: 522-530. DOI: 10.1016/S1470-2045(15)70122-1
    [24]
    Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial[J]. Lancet Oncol, 2018, 19: 1480-1492. DOI: 10.1016/S1470-2045(18)30700-9
    [25]
    Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma[J]. N Engl J Med, 2018, 378: 1277-1290. DOI: 10.1056/NEJMoa1712126
    [26]
    Reck M, Schenker M, Lee KH, et al. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase Ⅲ CheckMate 227 trial[J]. Eur J Cancer, 2019, 116: 137-147. DOI: 10.1016/j.ejca.2019.05.008
    [27]
    Paz-Ares LG, Ramalingam SS, Ciuleanu TE, et al. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial[J]. J Thorac Oncol, 2022, 17: 289-308. DOI: 10.1016/j.jtho.2021.09.010
    [28]
    Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2021, 22: 198-211. DOI: 10.1016/S1470-2045(20)30641-0
    [29]
    Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet, 2021, 397: 375-386. DOI: 10.1016/S0140-6736(20)32714-8
    [30]
    Kudo M. Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma[J]. Liver Cancer, 2022, 11: 87-93. DOI: 10.1159/000523702
    [31]
    Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study[J]. Lancet Oncol, 2017, 18: 1182-1191. DOI: 10.1016/S1470-2045(17)30422-9
    [32]
    Yau T, Kang YK, Kim TY, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial[J]. JAMA Oncol, 2020, 6: e204564. DOI: 10.1001/jamaoncol.2020.4564
    [33]
    朱军, 黄美金, 陈宏. 进展期胃癌免疫治疗的研究进展[J]. 癌症进展, 2022, 20: 1189-1193. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ202212021.htm
    [34]
    Tarhini AA, Kang N, Lee SJ, et al. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis[J]. J Immunother Cancer, 2021, 9: e002535. DOI: 10.1136/jitc-2021-002535
    [35]
    Govindan R, Szczesna A, Ahn MJ, et al. Phase Ⅲ Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer[J]. J Clin Oncol, 2017, 35: 3449-3457. DOI: 10.1200/JCO.2016.71.7629
    [36]
    Kang S, Wang X, Zhang Y, et al. First-Line Treatments for Extensive-Stage Small-Cell Lung Cancer With Immune Checkpoint Inhibitors Plus Chemotherapy: A Network Meta-Analysis and Cost-Effectiveness Analysis[J]. Front Oncol, 2021, 11: 740091.
    [37]
    Yu J, Ma S, Tian S, et al. Systematic Construction and Validation of a Prognostic Model for Hepatocellular Carcinoma Based on Immune-Related Genes[J]. Front Cell Dev Biol, 2021, 9: 700553. DOI: 10.3389/fcell.2021.700553
    [38]
    Cedres S, Felip E. 3-Year CheckMate743 outcomes: ringing in immunotherapy for the treatment of malignant pleural mesothelioma[J]. Ann Oncol, 2022, 33: 457-459. DOI: 10.1016/j.annonc.2022.03.004
    [39]
    Takei S, Kawazoe A, Shitara K. The New Era of Immunotherapy in Gastric Cancer[J]. Cancers (Basel), 2022, 14: 1054. DOI: 10.3390/cancers14041054
    [40]
    Weiss SA, Kluger H. CheckMate-067: Raising the Bar for the Next Decade in Oncology[J]. J Clin Oncol, 2022, 40: 111-113. http://pubmed.ncbi.nlm.nih.gov/34855466/
    [41]
    Zhang X, Wu T, Cai X, et al. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities[J]. Front Immunol, 2022, 13: 795972. DOI: 10.3389/fimmu.2022.795972
    [42]
    Cavillon A, Pouessel D, Houédé N, et al. Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase Ⅲ Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials[J]. Eur Urol, 2023, 25: S0302-2838(23)02619-2.
    [43]
    Owonikoko TK, Park K, Govindan R, et al. Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451[J]. J Clin Oncol, 2021, 39: 1349-1359. DOI: 10.1200/JCO.20.02212
    [44]
    Peters S, Pujol JL, Dafni U, et al. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy-results from the randomised phase Ⅱ ETOP/IFCT 4-12 STIMULI trial[J]. Ann Oncol, 2022, 33: 67-79. DOI: 10.1016/j.annonc.2021.09.011
    [45]
    Mariniello A, Novello S, Scagliotti GV, et al. Double immune checkpoint blockade in advanced NSCLC[J]. Crit Rev Oncol Hematol, 2020, 152: 102980. DOI: 10.1016/j.critrevonc.2020.102980
    [46]
    Rizvi NA, Cho BC, Reinmuth N, et al. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial[J]. JAMA Oncol, 2020, 6: 661-674. DOI: 10.1001/jamaoncol.2020.0237
    [47]
    Boyer M, Şendur M, Rodríguez-Abreu D, et al. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase Ⅲ KEYNOTE-598 Study[J]. J Clin Oncol, 2021, 39: 2327-2338. DOI: 10.1200/JCO.20.03579
    [48]
    Lee JY, Lee HT, Shin W, et al. Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy[J]. Nat Commun, 2016, 7: 13354. DOI: 10.1038/ncomms13354
    [49]
    He M, Chai Y, Qi J, et al. Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies[J]. Oncotarget, 2017, 8: 67129-67139. DOI: 10.18632/oncotarget.18004
    [50]
    Ramagopal UA, Liu W, Garrett-Thomson SC, et al. Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab[J]. Proc Natl Acad Sci USA, 2017, 114: E4223-E4232. http://europepmc.org/articles/PMC5448203/pdf/pnas.201617941.pdf
    [51]
    左乔竹, 覃文新. CTLA-4和PD-1信号通路在实体瘤治疗中的研究进展[J]. 生命科学, 2017, 29: 713-721. https://www.cnki.com.cn/Article/CJFDTOTAL-SMKX201708002.htm
    • Related Articles

  • Related Articles

    [1]WANG Pu, GAO Liming, ZHANG Wenyang, YE Ting, LI Hongyan, GUO Rui. Relationship Between Expressions of SDHx Genes and Immune Cell Infiltration in Pheochromocytoma/Paraganglioma[J]. Medical Journal of Peking Union Medical College Hospital. DOI: 10.12290/xhyxzz.2024-1093
    [2]LYU Zhengqin, ZHAO Yuhao, GUO Yuanyuan, LIU Beibei, LIU Jianmin. Research Progress on the Effect of Clinical Concomitant Medication on Efficacy of Immune Checkpoint Inhibitors in Urothelial Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(2): 394-399. DOI: 10.12290/xhyxzz.2023-0488
    [3]ZENG Xinying, WEN Xuejun, GUO Zhide, ZHANG Xianzhong. Advances in Synergistic Antitumor Effects of Radiopharmaceuticals Combined with Immune Checkpoint Inhibitors[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(4): 680-690. DOI: 10.12290/xhyxzz.2023-0159
    [4]WANG Shuo, DENG Yuntian, PENG Huan, ZHANG Xiangfeng. Progress in the Treatment of Non-small Cell Lung Cancer with Immune Checkpoint Inhibitors[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 409-415. DOI: 10.12290/xhyxzz.2022-0151
    [5]DAI Liyuan, SHI Yuankai, HAN Xiaohong. Advances in Dynamic Monitoring of Immune Checkpoint Inhibitors as the Prognostic Markers for Advanced Non-small Cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 287-295. DOI: 10.12290/xhyxzz.2021-0608
    [6]Gynecological Oncology Society of Chinese Medical Association. Clinical Practice Guidelines for Immune Checkpoint Inhibitor Therapy in Gynecological Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 854-880. DOI: 10.12290/xhyxzz.2021-0683
    [7]WU Ling-ge, XU Yan, LI Nai-shi. Thyrotoxicosis Related to Immune Checkpoint Inhibitors[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(1): 129-135. DOI: 10.3969/j.issn.1674-9081.2020.00.004
    [8]TANG Hui, YING Hong-yan, BAI Chun-mei. Application of Cyclin-dependent Kinase 4/6 Inhibitors in the Treatment of Malignancies and the Mechanism of Drug Resistance[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(6): 758-765. DOI: 10.3969/j.issn.1674-9081.2020.06.022
    [9]Yang GAO, Zhao SUN, Chun-mei BAI. Application of Immune-checkpoint Inhibitors in Recurrent/Metastatic Nasopharyngeal Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 626-630. DOI: 10.3969/j.issn.1674-9081.2020.05.021
    [10]Hui TANG, Jian-feng ZHOU, Chun-mei BAI. Clinical Progress of Immune Checkpoint Inhibitors in the Elderly[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(4): 459-464. DOI: 10.3969/j.issn.1674-9081.2020.04.018

  • Cited by

    Periodical cited type(31)

    1. 谭冰，曾巧莉，方凌燕，郭润民. 妊娠期糖尿病孕妇发生不良妊娠结局的危险因素分析及Nomogram预测模型构建. 中国性科学. 2024(02): 66-70 .
    2. 谢丽芬，欧阳山丹，戴小霞. 通脉降糖胶囊联合达格列净片治疗2型糖尿病的疗效及对患者胰岛功能的影响. 临床合理用药. 2024(09): 16-19 .
    3. 朱红梅，蔡丹，张艳丽. 妊娠相关暴发性1型糖尿病致死胎一例. 临床内科杂志. 2024(07): 503-504 .
    4. 袁坦，张媛媛，王艺梦，叶红丽. 基于多模式持续性健康管理的强化饮食干预在~(131)I治疗甲状腺功能亢进症合并糖尿病患者中的应用效果. 内科. 2023(01): 33-36+51 .
    5. 刘丹，倪铭晞，佟鑫垚，陈殿严. 2型糖尿病肾病患者外周血IL-4、INF-γ及TAFI表达及其与肾小球滤过功能的相关性. 川北医学院学报. 2023(04): 510-513 .
    6. 魏萍萍，李鑫屹. 上海市部分社区老年糖尿病患者血糖达标现状及医院—社区—家庭标准化管理模式干预效果. 中国初级卫生保健. 2023(06): 31-34+38 .
    7. 姜建珍，徐晓薇. 连续动态血糖监测在预防2型糖尿病患者住院期间发生低血糖的价值研究. 糖尿病新世界. 2023(17): 185-189 .
    8. 余秀琪，植春婷，李洁怡，申利群，邢舟，谢凤凤，张淼，韦凤超，韦都东，朱华，许立拔. 单次大剂量观察壮瑶药提取物对STZ所致高血糖小鼠的降血糖作用研究. 壮瑶药研究. 2023(03): 218-230+523-524 .
    9. 刘燕晶，张帆. 对暴发性1型糖尿病临床特征的探讨. 罕少疾病杂志. 2022(01): 89-92 .
    10. 刘卫娟，李蕊. 补脾益肾通络中药联合甲钴胺治疗糖尿病周围神经病变患者的疗效. 中国药物经济学. 2022(01): 75-78+82 .
    11. 肖梓栋，杨曙晖，吴丽楠，纪宝刁. 基于网络信息化系统的多科协作院内血糖管理模式探讨. 湖南师范大学学报(医学版). 2022(01): 64-67 .
    12. 张琳. 整体护理干预在老年糖尿病性白内障患者小切口摘除术围手术期中的应用. 内蒙古医学杂志. 2022(03): 371-372+375 .
    13. 郭翔，温建军. 用药指导对老年糖尿病患者血糖控制效果及安全性的影响. 中国初级卫生保健. 2022(04): 42-44 .
    14. 陈晓倩，叶励新，江月卿. 中西医结合护理在中风伴糖尿病患者中的应用效果. 中外医学研究. 2022(12): 74-78 .
    15. 徐磊，岳妍秋. 老年高血压患者慢性肾脏病发病情况及其危险因素. 中国卫生工程学. 2022(04): 583-585 .
    16. 魏慧琴，陈霞飞，卢阿芬，武丽丽，郑三燕，李仙丽. 正念减压训练对糖尿病患者睡眠质量、应对适应能力及血糖控制的影响. 世界睡眠医学杂志. 2022(09): 1729-1731 .
    17. 梁健，刘强，陈燕，胡玉花，洪芸芸，张燕. 度拉糖肽联合二甲双胍、达格列净对初诊2型糖尿病患者糖脂代谢的影响. 内科. 2022(05): 495-498+504 .
    18. 郭明凤，周兵. 细菌性肝脓肿合并糖尿病的临床特征. 中国普外基础与临床杂志. 2021(02): 230-235 .
    19. 林静娜，辜智强. 血清VEGF、apelin、HO-1水平与不同分型糖尿病视网膜病变患者的相关性研究. 国际检验医学杂志. 2021(08): 999-1002 .
    20. 李丹丹，杨亚兰. 接种23价肺炎及流感疫苗在老年糖尿病患者中的效果及安全性评价. 黑龙江医药科学. 2021(02): 11-14 .
    21. 王利平. 阿卡波糖和胰岛素治疗老年2型糖尿病的效果和安全性. 中国当代医药. 2021(11): 76-78 .
    22. 吴会玲，侯凤辉，娄侠，付晓燕. 替罗非班联合阿司匹林和氯吡格雷治疗糖尿病合并急性心肌梗死的临床研究. 药物评价研究. 2021(06): 1296-1300 .
    23. 虎静，李红梅. 仅通过饮食和运动控制血糖的绝经后2型糖尿病患者中血脂、骨代谢与骨密度的相关性研究. 中国骨质疏松杂志. 2021(07): 1022-1026+1060 .
    24. 杨冰，马国斌. 低脂饮食和低碳水化合物饮食对糖尿病肥胖老年患者能量消耗和身体成分的影响比较. 中国老年学杂志. 2021(20): 4372-4375 .
    25. 肖小敏，刘志云. 二甲双胍在社区糖尿病中对患者血糖控制的效果观察. 中国实用医药. 2021(28): 148-150 .
    26. 王黎明，王莹. 全科医生模式联合健康教育对糖尿病合并病毒性肝炎患者的干预效果. 中国校医. 2021(10): 747-749 .
    27. 翟洪漫. 超声对冠心病颈动脉粥样斑块诊断价值的疗效分析. 中国医疗器械信息. 2021(22): 101-103 .
    28. 刘红梅，高晓凤，卢美雪. 八段降糖操联合生活指导在糖尿病患者护理中的应用分析. 医学食疗与健康. 2021(14): 117-118 .
    29. 杨丽萍，周敏，付亚红. “医-护-患”三人行模式联合微信平台在2型糖尿病患者自我管理中的应用. 中国当代医药. 2021(36): 51-53 .
    30. 张义，杨清煜，王雨，夏伟年，陈龙菊. 葛根素对糖尿病及其并发症保护作用的研究进展. 湖北民族大学学报(医学版). 2020(01): 82-85 .
    31. 胡美凤. PDCA循环在非内分泌科胰岛素注射质量管理中的应用. 实用中西医结合临床. 2020(14): 138-139 .

    Other cited types(12)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1098) PDF downloads (95) Cited by(43)
    Related
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

      Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return
      x Close Forever Close